Picture of GSK logo

GSK GSK Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Momentum

Relative Strength (%)
1m-8.36%
3m-7.54%
6m+5.99%
1yr+9.6%
Volume Change (%)
10d/3m+30.83%
Price vs... (%)
52w High-12.01%
50d MA-4.84%
200d MA+2.34%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)9.57
PEG Ratio (f)0.87
EPS Growth (f)12.33%
Dividend Yield (f)3.88%
Valuation (ttm)IndustryMarket
Price to Book Value4.81
Price to Tang. Bookn/a
Price to Free Cashflow12.56
Price to Sales2.16
EV to EBITDA9.52

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital15.91%
Return on Equity34.95%
Operating Margin20.02%

Financial Summary

Year End 31st DecUnit201920202021202220232024E2025ECAGR / Avg
Total Revenue£m33,75424,35424,69629,32430,32831,722.7933,734.69-0.32%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+58.64-53.46-13.66+67.65+22.91+13.83+10.78n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of GSK EPS forecast chart

Profile Summary

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Directors

Last Annual
December 31st, 2023
Last Interim
March 31st, 2024
Incorporated
December 6th, 1999
Public Since
May 22nd, 1972
No. of Shareholders
61,745
No. of Employees
70,212
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
4,144,963,782

GSK Share Price Performance

Upcoming Events for GSK

Q2 2024 GSK plc Earnings Release

Q3 2024 GSK plc Earnings Release

Similar to GSK

Picture of Alliance Pharma logo

Alliance Pharma

gb flag iconLondon Stock Exchange

Picture of Animalcare logo

Animalcare

gb flag iconLondon Stock Exchange

Picture of Argent BioPharma logo

Argent BioPharma

gb flag iconLondon Stock Exchange

Picture of AstraZeneca logo

AstraZeneca

gb flag iconLondon Stock Exchange

Picture of Beximco Pharmaceuticals logo

Beximco Pharmaceuticals

gb flag iconLondon Stock Exchange

FAQ